{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Saoud C"],"funding":["NCI NIH HHS"],"pagination":["1302-1317"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12150273"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["48(10)"],"pubmed_abstract":["GLI1 -altered mesenchymal tumor is a recently described distinct pathologic entity with an established risk of malignancy, being defined molecularly by either GLI1 gene fusions or amplifications. The clinicopathologic overlap of tumors driven by the 2 seemingly distinct mechanisms of GLI1 activation is still emerging. Herein, we report the largest series of molecularly confirmed GLI1 -altered mesenchymal neoplasms to date, including 23 GLI1- amplified and 15 GLI1 -rearranged new cases, and perform a comparative clinicopathologic, genomic, and survival investigation. GLI1- rearranged tumors occurred in younger patients (42 vs. 52 y) and were larger compared with GLI1 -amplified tumors (5.6 cm vs. 1.5 cm, respectively). Histologic features were overall similar between the 2 groups, showing a"],"journal":["The American journal of surgical pathology"],"pubmed_title":["A Comprehensive Clinicopathologic and Molecular Reappraisal of GLI1 -altered Mesenchymal Tumors with Pooled Outcome Analysis Showing Poor Survival in GLI1 - amplified Versus GLI1- rearranged Tumors."],"pmcid":["PMC12150273"],"funding_grant_id":["P30 CA008748","P50 CA217694"],"pubmed_authors":["Albritton K","Michal M","Antonescu CR","Dermawan JK","Dashti N","Saoud C","Dickson BC","Agaimy A","Chen JF","Kosemehmetoglu K","Agaram NP","Rosenblum MK","Din NU"],"additional_accession":[]},"is_claimable":false,"name":"A Comprehensive Clinicopathologic and Molecular Reappraisal of GLI1 -altered Mesenchymal Tumors with Pooled Outcome Analysis Showing Poor Survival in GLI1 - amplified Versus GLI1- rearranged Tumors.","description":"GLI1 -altered mesenchymal tumor is a recently described distinct pathologic entity with an established risk of malignancy, being defined molecularly by either GLI1 gene fusions or amplifications. The clinicopathologic overlap of tumors driven by the 2 seemingly distinct mechanisms of GLI1 activation is still emerging. Herein, we report the largest series of molecularly confirmed GLI1 -altered mesenchymal neoplasms to date, including 23 GLI1- amplified and 15 GLI1 -rearranged new cases, and perform a comparative clinicopathologic, genomic, and survival investigation. GLI1- rearranged tumors occurred in younger patients (42 vs. 52 y) and were larger compared with GLI1 -amplified tumors (5.6 cm vs. 1.5 cm, respectively). Histologic features were overall similar between the 2 groups, showing a","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-03T23:34:58.726Z","creation":"2026-05-03T03:11:52.811Z"},"accession":"S-EPMC12150273","cross_references":{"pubmed":["38934567"],"doi":["10.1097/pas.0000000000002272","10.1097/PAS.0000000000002272"]}}